Cervical Dysplasia Center

The Johns Hopkins Cervical Dysplasia Center focuses on the management and prevention of cervical HPV disease. If you have had an abnormal Pap smear, obstetricians and gynecologists at our center are available for gynecologic checkups and second opinion visits, as well as evaluation to determine if you are a good candidate for clinical trial participation.

Request an Appointment

Before making an appointment, please fax a copy of your most recent pathology report to 443-769-1205. Then, call 443-997-0400 to get set up in the Johns Hopkins system. Once you are in the system and have your records sent, you can contact our office below to set up an appointment:

Call Us

Email Us

The link between HPV and cervical cancer is bigger than the link between smoking and lung cancer."

-Dr. Connie Trimble, in her TedX Talk, Kicking Cancer's Butt
Dr. Connie Trimble

Care Locations

Dr. Connie Trimble sees patients at the Johns Hopkins Outpatient Center (on Tuesday mornings) and Green Spring Station (on the first Friday of the month).
  • Johns Hopkins Outpatient Center

    The Johns Hopkins Outpatient Center is renamed the Levi Watkins, Jr., M.D., Outpatient Center, effective June 2023. Dr. Watkins was a pioneer in cardiac surgery and civil rights who died in 2015.

    exterior of the Johns Hopkins Outpatient Center
  • Green Spring Station

    The Johns Hopkins Kimmel Cancer Center’s Medical Oncology practice at Green Spring Station in Lutherville, Maryland, opened its doors in a brand new, spacious facility on June 3, 2019. Located on the first floor of Pavilion III, the practice features programs in breast cancer, lymphoma, lung cancer, melanoma, ovarian cancer, gastrointestinal cancers, and genitourinary cancers.

    Johns Hopkins Health Care & Surgery Center — Green Spring Station, Lutherville

Our Team


Cornelia Liu Trimble, M.D.

  • Professor of Gynecology and Obstetrics
  • Professor of Oncology
  • Professor of Pathology

Research and Clinical Trials

We are interested in how immune responses occur in the cervix. The focus of our translational research is on developing immune therapies for disease caused by human papillomavirus (HPV). HPV infection causes more cancers than any other virus in the world.

Cervical cancer is the most common cancer caused by HPV, and although we have known how to screen for it for over half a century, it remains the second most common cause of cancer death in women. Although the preventive vaccines are a public health milestone, they prevent HPV infections, but are not designed to make immune responses to treat HPV.

We are testing different strategies to make immune responses that could treat HPV disease.

Clinical Trials

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Overview: This phase I trial is studying the side effects and best dose of vaccine therapy and to see how well it works when given with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia.

Contact: Mihaela Paradis: 410-502-0512 or [email protected]

More information from clinicaltrials.gov